[Abatacept in the treatment of active rheumatoid arthritis]

Ugeskr Laeger. 2009 Jan 19;171(4):214-7.
[Article in Danish]

Abstract

Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway.

Publication types

  • English Abstract

MeSH terms

  • Abatacept
  • Adult
  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Immunoconjugates / therapeutic use*
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Immunoconjugates
  • Immunosuppressive Agents
  • Abatacept